Researchers at Boston Medical Center (BMC) and Boston University School of Medicine (BUSM), in collaboration with Columbia University Irving Medical Center (CUIMC), are leading a national, multi-site ...
DUBLIN, Ireland and BAGSVÆRD, Denmark, July 12, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have ...
Prothena Corporation PRTA announced a collaboration with Denmark-based Novo Nordisk NVO, whereby the latter will acquire Prothena’s clinical-stage antibody, PRX004, and broader ATTR amyloidosis ...
News-Medical.Net on MSN
Atrial dysfunction assessment tool may help identify stroke risk in people with ATTR-CM
A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a non-invasive assessment tool may help identify those at increased risk, ...
Please provide your email address to receive an email when new articles are posted on . Alnylam announced positive top-line results of its phase 3 trial of vutrisiran for the treatment of ATTR ...
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...
The US Food and Drug Administration (FDA) has declined to approve the RNA interference (RNAi) therapeutic agent patisiran (Onpattro, Alnylam Pharmaceuticals) for treatment of transthyretin-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback